Modulating heart signaling to improve treatment for cardiomyopathy
Cardiomyocyte selective modulation of natriuretic peptide signaling in cardiomyopathy
This study is looking at a new way to help people with cardiomyopathy by boosting the natural signals in their heart cells that keep the heart healthy, which could lead to better treatments with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10980673 on NIH RePORTER |
What this research studies
This research investigates how to selectively enhance natriuretic peptide signaling in heart cells to better manage cardiomyopathy, a condition that can lead to heart failure. The approach focuses on preventing the breakdown of beneficial peptides that help regulate heart function, potentially reducing the risk of severe complications like sudden death. By using targeted therapies, the research aims to minimize side effects associated with current treatments and improve patient outcomes. Patients with cardiomyopathy may be able to participate in trials that explore these new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cardiomyopathy who are at risk for heart failure or sudden cardiac events.
Not a fit: Patients with non-cardiomyopathy related heart conditions or those who do not have significant heart dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cardiomyopathy, reducing the risk of heart failure and sudden death.
How similar studies have performed: Previous studies have shown promising results with similar approaches, particularly in the use of neprilysin inhibitors in treating dilated cardiomyopathy.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Becker, Jason — University of Pittsburgh at Pittsburgh
- Study coordinator: Becker, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.